Premium
Longeveron Inc (LGVN)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-01 | Dr. Nataliya AgafonovaChief Medical Officer | -13,15k | 14,72k | Sale to Issuer | 1,12 | 203,42k | -6,07% |
| 2026-04-01 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | -13,15k | 14,72k | Sale to Issuer | 1,12 | 215,69k | -5,74% |
| 2026-04-01 | Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls | -8,63k | 9,67k | Sale to Issuer | 1,12 | 191,54k | -4,31% |
| 2026-04-01 | Mr. Stephen H. WillardCEO | -4,74k | 5,31k | Sale to Issuer | 1,12 | 289,73k | -1,61% |
| 2026-04-01 | Mr. Paul T. LehrGeneral Counsel & Secretary | -5,61k | 6,28k | Sale to Issuer | 1,12 | 338,57k | -1,63% |
| 2026-03-02 | Mr. Stephen H. WillardCEO | -105,53k | 57,52k | Sale to Issuer | 0,55 | 294,47k | -26,38% |
| 2026-01-02 | Mr. Than PowellInitié | -2,46k | 1,46k | Sale to Issuer | 0,59 | 125,59k | -1,92% |
| 2026-01-02 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | -10,25k | 6,08k | Sale to Issuer | 0,59 | 228,83k | -4,29% |
| 2026-01-02 | Mr. Paul T. LehrGeneral Counsel & Secretary | -6,95k | 4,12k | Sale to Issuer | 0,59 | 344,18k | -1,98% |
| 2026-01-02 | Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls | -10,70k | 6,35k | Sale to Issuer | 0,59 | 200,18k | -5,07% |
| 2026-01-02 | Dr. Nataliya AgafonovaChief Medical Officer | -10,25k | 6,08k | Sale to Issuer | 0,59 | 216,56k | -4,52% |
| 2025-10-01 | Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls | -7,61k | 5,65k | Sale to Issuer | 0,74 | 210,88k | -3,48% |
| 2025-10-01 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | -11,88k | 8,82k | Sale to Issuer | 0,74 | 239,08k | -4,73% |
| 2025-10-01 | Mr. Paul T. LehrGeneral Counsel & Secretary | -4,94k | 3,67k | Sale to Issuer | 0,74 | 351,13k | -1,39% |
| 2025-10-01 | Dr. Nataliya AgafonovaChief Medical Officer | -11,88k | 8,82k | Sale to Issuer | 0,74 | 226,81k | -4,98% |
| 2025-10-01 | Mr. Than PowellInitié | -2,39k | 1,77k | Sale to Issuer | 0,74 | 128,06k | -1,83% |
| 2025-08-11 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | 11,77k | 0,00 | Achat | - | 250,96k | 4,92% |
| 2025-08-11 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | 29,42k | 0,00 | Open Market Derivative Acquisition | 0,85 | 29,42k | - |
| 2025-08-11 | Mr. Khoso BaluchInitié | 11,77k | 0,00 | Achat | - | 52,52k | 28,87% |
| 2025-08-11 | Mr. Khoso BaluchInitié | 29,42k | 0,00 | Open Market Derivative Acquisition | 0,85 | 29,42k | - |
| 2025-07-01 | Mr. Paul T. LehrGeneral Counsel & Secretary | -1,56k | 2,00k | Sale to Issuer | 1,28 | 254,07k | -0,61% |
| 2025-07-01 | Mr. Mohamed Wa'el Ahmed HashadInitié | -13,15k | 16,83k | Sale to Issuer | 1,28 | 240,90k | -5,17% |
| 2025-07-01 | Dr. Nataliya AgafonovaChief Medical Officer | -7,43k | 9,51k | Sale to Issuer | 1,28 | 136,70k | -5,16% |
| 2025-07-01 | Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls | -4,60k | 5,89k | Sale to Issuer | 1,28 | 116,49k | -3,80% |
| 2025-07-01 | Ms. Lisa A. LocklearCFO, Exec. VP & Treasurer | -7,43k | 9,51k | Sale to Issuer | 1,28 | 137,20k | -5,14% |
| 2025-06-23 | Mr. Paul T. LehrGeneral Counsel & Secretary | -64,16k | 73,78k | Sale to Issuer | 1,15 | 255,64k | -20,06% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
